方法对比

	通用健康问卷-12 (GHQ-12)	老年抑郁量表 (GDS)	医院焦虑抑郁量表 (HADS)
领域	临床心理学	临床心理学	临床心理学
方法族	Process / pipeline	Process / pipeline	Process / pipeline
起源年份	1992	1982	1983
提出者	David P. Goldberg	Jerome A. Yesavage, Terry L. Brink, and colleagues	Andrew S. Zigmond and Richard P. Snaith
类型	Psychiatric symptom screening	Age-appropriate depression screening	Anxiety and depression screening in medical populations
开创性文献	Goldberg, D. P. (1972). The detection of psychiatric illness by questionnaire. Oxford University Press.	Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982). Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research, 17(1), 37-49.	Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67(6), 361-370.
别名	GHQ-12, GHQ	GDS, GDS-15, GDS-30	HADS, HADS-A, HADS-D
相关	5	5	4
摘要	The General Health Questionnaire-12 (GHQ-12) is a brief, 12-item self-report screening instrument for psychological distress and mental health problems in the general population. Developed by David P. Goldberg, the GHQ-12 is the most widely used short form of the longer General Health Questionnaire series. It is designed for rapid detection of minor psychiatric morbidity and assessment of psychological well-being in clinical, occupational health, and community settings.	The Geriatric Depression Scale (GDS) is a 30-item self-report depression screening instrument specifically designed for older adults. Developed by Yesavage, Brink, and colleagues in 1982, the GDS addresses the unique presentation of depression in aging populations, where symptoms may differ from younger adults. A validated 15-item short form (GDS-15) is widely used in primary care and community settings for rapid screening.	The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report instrument measuring anxiety and depression symptoms in medically ill populations. Developed by Zigmond and Snaith in 1983, the HADS was specifically designed for hospital and general medical settings where somatic symptoms of medical illness may confound assessment. It remains the standard anxiety-depression measure in medical, oncology, and cardiac populations worldwide.